- Conditions
- Idiopathic Parkinson Disease
- Interventions
- VTX3232
- Drug
- Lead sponsor
- Zomagen Biosciences Ltd.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 33,591
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Tuberculosis, HIV
- Interventions
- Efavirenz (EFV), TMC207
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 5
- States / cities
- San Francisco, California • Baltimore, Maryland • Chapel Hill, North Carolina + 2 more
- Conditions
- HIV-1, HIV Infection
- Interventions
- DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 2
- States / cities
- Tampa, Florida • The Bronx, New York
- Conditions
- Venous Thromboembolism
- Interventions
- Apixaban, Standard of Care
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 0 Days to 17 Years
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 84
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 47 more
- Conditions
- ALS
- Interventions
- MT-1186
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Rogers, Arkansas • San Francisco, California + 18 more
- Conditions
- Cancer
- Interventions
- ziv-aflibercept
- Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 2
- States / cities
- New York, New York • Nashville, Tennessee
- Conditions
- Nasolabial Folds
- Interventions
- Restylane and Restylane-L
- Device
- Lead sponsor
- Medicis Global Service Corporation
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- Coral Gables, Florida • Hunt Valley, Maryland • Mount Kisco, New York
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Nusinersen, Sham Procedure
- Drug · Procedure
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Not listed
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Hartford, Connecticut • Baltimore, Maryland + 3 more
- Conditions
- Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Interventions
- LAVA-051, Interleukin 2
- Biological
- Lead sponsor
- Lava Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 2 more
- Conditions
- Insomnia
- Interventions
- APD125
- Drug
- Lead sponsor
- Arena Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 173 participants
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- Interventions
- HU6, Placebo
- Drug · Other
- Lead sponsor
- Rivus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 20
- States / cities
- Chula Vista, California • Los Angeles, California • Montclair, California + 13 more
- Conditions
- Oral Mucositis
- Interventions
- SCV-07, Placebo
- Drug
- Lead sponsor
- SciClone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 49
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more
- Conditions
- HIV Infections
- Interventions
- HIV-1 Peptide Vaccine, Microparticulate Monovalent, HIV-1 Peptide Immunogen, Multivalent
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Rochester, New York • Seattle, Washington
- Conditions
- HIV Infection
- Interventions
- Vitamin D3 50,000 IU, Vitamin D3 placebo
- Dietary Supplement
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 16 Years to 24 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 11 more
- Conditions
- Asthma
- Interventions
- Reslizumab, Saline
- Biological · Other
- Lead sponsor
- Ception Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 24
- States / cities
- Orange, California • Centennial, Colorado • Colorado Springs, Colorado + 20 more
- Conditions
- HIV-1 Infection
- Interventions
- Islatravir, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 242 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- Hollywood, Florida • Baltimore, Maryland • Lincoln, Nebraska + 1 more
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain, Glioblastoma Multiforme, Adult, Recurrent Glioblastoma, Astrocytoma, Malignant, Astrocytoma of Brain
- Interventions
- Re-resection, Temozolomide, Lomustine, Re-irradiation, Experimental therapy, Best supportive care
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- Jasper Gerritsen
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 464 participants
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- San Francisco, California • Boston, Massachusetts
- Conditions
- Asthma
- Interventions
- Lebrikizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,068 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 54 more
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Astrocytoma, Oligodendroglioma
- Interventions
- 131I-TM601
- Drug
- Lead sponsor
- TransMolecular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Grand Rapids, Michigan + 1 more
- Conditions
- Liver Cancer
- Interventions
- Drug Eluting Bead Transarterial Chemoembolization, Nivolumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 9
- States / cities
- St Louis, Missouri • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
- Conditions
- Spinal Cord Injury Cervical, Spinal Cord Injury Thoracic, Spinal Cord Injury, Acute, Spinal Cord Injury, Spinal Cord Injury, Chronic
- Interventions
- OPC1
- Biological
- Lead sponsor
- Lineage Cell Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 2
- States / cities
- Downey, California • La Jolla, California
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Fallopian Tube Endometrioid Adenocarcinoma, Unresectable Fallopian Tube High Grade Serous Adenocarcinoma, Unresectable Ovarian Endometrioid Adenocarcinoma, Unresectable Ovarian High Grade Serous Adenocarcinoma, Unresectable Primary Peritoneal Endometrioid Adenocarcinoma, Unresectable Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions
- Biopsy Procedure, Carboplatin, Ipatasertib, Paclitaxel
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 8
- States / cities
- San Francisco, California • Augusta, Georgia • Cleveland, Ohio + 5 more
- Conditions
- Mycobacterium Infections, Nontuberculous
- Interventions
- ALIS, Azithromycin, Ethambutol, ELC (matching placebo for ALIS)
- Drug
- Lead sponsor
- Insmed Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 425 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Fresno, California • Los Angeles, California + 71 more
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia, Refractory B-cell Acute Lymphoblastic Leukemia
- Interventions
- CTL019 T-cells
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 10 more